388 related articles for article (PubMed ID: 34289753)
1. Therapeutic potential of biologics in prurigo nodularis.
Müller S; Bieber T; Ständer S
Expert Opin Biol Ther; 2022 Jan; 22(1):47-58. PubMed ID: 34289753
[TBL] [Abstract][Full Text] [Related]
2. Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.
Müller S; Zeidler C; Ständer S
Am J Clin Dermatol; 2024 Jan; 25(1):15-33. PubMed ID: 37717255
[TBL] [Abstract][Full Text] [Related]
3. A critical evaluation of nemolizumab for prurigo nodularis.
Brooks SG; Yosipovitch G
Expert Rev Clin Immunol; 2024 Jun; 20(6):577-587. PubMed ID: 38217530
[TBL] [Abstract][Full Text] [Related]
4. Chronic Prurigo.
Thünemann J; Müller S; Steinbrink K; Ständer S; Zeidler C
J Dtsch Dermatol Ges; 2024 Jun; 22(6):813-823. PubMed ID: 38722190
[TBL] [Abstract][Full Text] [Related]
5. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
[TBL] [Abstract][Full Text] [Related]
6. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J
Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis.
Nilforoushzadeh MA; Heidari N; Ghane Y; Heidari A; Hajikarim-Hamedani A; Hosseini S; Jaffary F; Najar Nobari M; Tavakolzadeh P; Najar Nobari N
Inflammopharmacology; 2024 Apr; 32(2):991-1003. PubMed ID: 38332383
[TBL] [Abstract][Full Text] [Related]
8. INDIVIDUAL ARTICLE: Management of Prurigo Nodularis.
Elmariah SB; Tao L; Valdes-Rodriguez R; Laquer V
J Drugs Dermatol; 2023 Dec; 22(12):SF365502s15-SF365502s22. PubMed ID: 38051855
[TBL] [Abstract][Full Text] [Related]
9. Non-Atopic Chronic Nodular Prurigo (Prurigo Nodularis Hyde): A Systematic Review of Best-Evidenced Treatment Options.
Frølunde AS; Wiis MAK; Ben Abdallah H; Elsgaard S; Danielsen AK; Deleuran M; Vestergaard C
Dermatology; 2022; 238(5):950-960. PubMed ID: 35417906
[TBL] [Abstract][Full Text] [Related]
10. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulating Agents as Antipruritics.
Erickson S; Nahmias Z; Rosman IS; Kim BS
Dermatol Clin; 2018 Jul; 36(3):325-334. PubMed ID: 29929604
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and treatment algorithm for chronic nodular prurigo.
Ständer HF; Elmariah S; Zeidler C; Spellman M; Ständer S
J Am Acad Dermatol; 2020 Feb; 82(2):460-468. PubMed ID: 31310842
[TBL] [Abstract][Full Text] [Related]
13. Prurigo nodularis: new insights into pathogenesis and novel therapeutics.
Liao V; Cornman HL; Ma E; Kwatra SG
Br J Dermatol; 2024 May; 190(6):798-810. PubMed ID: 38345154
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of dupilumab in prurigo nodularis in elderly patient.
Giura MT; Viola R; Fierro MT; Ribero S; Ortoncelli M
Dermatol Ther; 2020 Jan; 33(1):e13201. PubMed ID: 31856368
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
Husein-ElAhmed H; Steinhoff M
J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis.
Williams KA; Roh YS; Brown I; Sutaria N; Bakhshi P; Choi J; Gabriel S; Chavda R; Kwatra SG
Expert Rev Clin Pharmacol; 2021 Jan; 14(1):67-77. PubMed ID: 33191806
[No Abstract] [Full Text] [Related]
17. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.
Ständer S; Yosipovitch G; Lacour JP; Legat FJ; Paul C; Reich A; Chaouche K; Ahmad F; Piketty C
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1820-1825. PubMed ID: 35766128
[TBL] [Abstract][Full Text] [Related]
18. Single-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis.
Alkon N; Assen FP; Arnoldner T; Bauer WM; Medjimorec MA; Shaw LE; Rindler K; Holzer G; Weber P; Weninger W; Freystätter C; Chennareddy S; Kinaciyan T; Farlik M; Jonak C; Griss J; Bangert C; Brunner PM
J Allergy Clin Immunol; 2023 Aug; 152(2):420-435. PubMed ID: 37210042
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab for the Treatment of Prurigo Nodularis.
Alkhaleefa A; Woo TE; Parsons L
Skin Therapy Lett; 2023 Nov; 28(6):7-9. PubMed ID: 38016088
[TBL] [Abstract][Full Text] [Related]
20. Chronic prurigo.
Misery L
Br J Dermatol; 2022 Oct; 187(4):464-471. PubMed ID: 35656799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
